X4 Pharmaceuticals, Inc
XFOR Nasdaq
SEC CIK 1501697
Follow X4 Pharmaceuticals
Weekly email: filings, results
Revenue, last quarter
$2.9M
+63.1% vs same quarter last year
Net income
−$20.2M
+32.3% vs same quarter last year
EPS, diluted
−$0.16
+76.8% vs same quarter last year
Operating cash flow
−$20.2M
+27.4% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $35.1M | −$79.2M |
| FY24 | $2.6M | −$37.5M |
| FY23 | $0 | −$101.2M |
| FY22 | $0 | −$93.9M |
| FY21 | $0 | −$88.7M |
| FY20 | $3M | −$62.1M |
| FY19 | $0 | −$52.8M |
| FY18 | $0 | −$33.3M |
| FY17 | - | −$22M |
| FY16 | - | −$23M |
| FY15 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | −247.4% | −225.6% |
| FY24 | −1423.6% | −1464.6% |
| FY23 | - | - |
| FY22 | - | - |
| FY21 | - | - |
| FY20 | −1995.8% | −2071% |
| FY19 | - | - |
| FY18 | - | - |
| FY17 | - | - |
| FY16 | - | - |
| FY15 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$85.6M |
| FY24 | −$131.2M |
| FY23 | −$96.6M |
| FY22 | −$77.2M |
| FY21 | −$71.5M |
| FY20 | −$60.2M |
| FY19 | −$48.2M |
| FY18 | −$25.4M |
| FY17 | −$21.7M |
| FY16 | −$21.7M |
| FY15 | - |
Show the numbers
| Year | Buybacks |
|---|---|
| FY25 | - |
| FY24 | - |
| FY23 | $0 |
| FY22 | $0 |
| FY21 | $2M |
| FY20 | $0 |
| FY19 | $0 |
| FY18 | - |
| FY17 | - |
| FY16 | - |
| FY15 | - |
- X4 Pharmaceuticals
- Healthcare median
Show the numbers
| Year | X4 Pharmaceuticals | Healthcare median |
|---|---|---|
| FY25 | −225.6% | −30.6% |
| FY24 | −1464.6% | −47% |
| FY23 | - | −58% |
| FY22 | - | −80.4% |
| FY21 | - | −71.8% |
| FY20 | −2071% | −62.2% |
| FY19 | - | −46.2% |
| FY18 | - | −49.6% |
| FY17 | - | −45.9% |
| FY16 | - | −36% |
| FY15 | - | −37.8% |